Hansa Biopharma AB
OTC:HNSBF
Gross Margin
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Peer Comparison
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| SE |
|
Hansa Biopharma AB
STO:HNSA
|
3.3B SEK |
Loading...
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
Loading...
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
412.7B USD |
Loading...
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
206.6B USD |
Loading...
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
186.2B USD |
Loading...
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
123.6B USD |
Loading...
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
Loading...
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
83.1B USD |
Loading...
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
70B AUD |
Loading...
|
|
| NL |
|
argenx SE
XBRU:ARGX
|
39.4B EUR |
Loading...
|
|
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR |
Loading...
|
Market Distribution
| Min | -855 316.7% |
| 30th Percentile | 30.8% |
| Median | 44.8% |
| 70th Percentile | 66% |
| Max | 113 764.6% |
Other Profitability Ratios
Hansa Biopharma AB
Glance View
Hansa Biopharma AB focuses on novel immunomodulatory enzymes, which treats rare immunoglobulin G-mediated autoimmune conditions, transplant rejection and cancer. The company is headquartered in Lund, Skane and currently employs 141 full-time employees. The company went IPO on 2007-10-17. The Company’s operations consist of research and development for drug discovery. The firm conducts several projects, among which primary are IdeS (Immunoglobulin G-degrading enzyme of Streptococcus pyogenes) and HBP-assay (Heparin Binding Protein-assay). IdeS’s goal is to enable transplantation that prevents antibody-mediated rejection. HBP-assay is a diagnostic method that aims to predict severe sepsis in patients with infectious disease symptoms. The Company’s patent portfolio consists of several patent families that geographically cover numerous jurisdictions, including the United States, Europe and Japan.
See Also
Gross Margin is calculated by dividing the Gross Profit by the Revenue.
The current Gross Margin for Hansa Biopharma AB is 62.4%, which is above its 3-year median of 58.3%.
Over the last 3 years, Hansa Biopharma AB’s Gross Margin has decreased from 75.1% to 62.4%. During this period, it reached a low of 42.9% on Jun 30, 2024 and a high of 75.1% on Mar 31, 2023.
